🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆ Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆
Clinical Trials in Egypt / NCT07598253
Starting soon Not applicable

Intra-articular Injection of Medications in TMJ After Arthrocentsis

NCT07598253 · tracked via the Priya Life Science Egypt tracker
Phase
Not applicable
Started
2026-06-01
Last updated
2026-05-22

Condition(s) studied

Internal Derangement

Investigational drug(s) / intervention(s)

Arthrocentesis with ringer solutionArthrocentesis with ringer solution

Arthrocentesis with ringer solution: HA + Corticosteroid Group Patients receive intra-articular injection of a hyaluronic acid (HA) and corticosteroid mixture after arthrocentesis.

Arthrocentesis with ringer solution: HA + PRP Group Patients receive intra-articular injection of a hyaluronic acid (HA) and platelet-rich plasma (PRP) mixture after arthrocentesis

Study summary

The aim of this study: to evaluate the injection of hyaluronic acid and corticosteroids mixture leads to better clinical outcomes in terms of improve maximum mouth opening and reduce pain compared with hyaluronic acid and prp mixture in patients with TMJ internal derangement .

Eligibility

Sex
ALL
Min age
18 Years
Max age
60 Years
Healthy volunteers
No
Inclusion Criteria: * Patients should have one or more signs and symptoms of these * Symptoms: Patients who report typical symptoms of TMJ dysfunction, such as pain, discomfort, or clicking sounds in the joint, especially when opening or closing the mouth. * Mouth Opening: Limited range of motion or difficulty with full mouth opening. * Clicking: Audible clicking. * Pain: Pain or tenderness around the TMJ, often radiating to the ear, temple, or neck. Exclusion Criteria: * \* Previously diagnosed hematological and neurological conditions; * Previous malignant head and neck neoplasms; * Uncooperative patients.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Faculty of dentistry cairo university Cairo Cairo Governorate

More Cairo University trials in Egypt

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07598253 on ClinicalTrials.gov ↗ ← All trials in Egypt